Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ADVM | Adverum Biotechnologies, Inc. | 2025-10-30 18:51:18 | 4.23 | 0 | -0.01 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADVM | 0001501756 | Adverum Biotechnologies, Inc. | US00773U2078 | 529900ZEDOOZL1EWHJ89 | 205258327 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 100 CARDINAL WAY | REDWOOD CITY | CA | 94063 | UNITED STATES | US | (650) 649-1004 | 100 CARDINAL WAY, REDWOOD CITY, CA, 94063 | 100 CARDINAL WAY, REDWOOD CITY, CA, 94063 | Avalanche Biotechnologies, Inc. | — | 2006 | Laurent Fischer | 100 | https://adverum.com | 136,700,000 | 20,848,000 | 20,984,161 | Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD). | 2025-10-30 16:30:29 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 136,700,000 | -15,100,000 | -9.9473 | 20,890,540 | -186,658,612 | -89.9347 |
| 2023 | 151,800,000 | 36,900,000 | 32.1149 | 207,549,152 | 106,989,861 | 106.3948 |
| 2022 | 114,900,000 | -205,400,000 | -64.1274 | 100,559,291 | 1,808,574 | 1.8315 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Rabia Gurses Ozden | Chief Medical Officer | 2024 | 281,250 | 150,000 | 0 | 112,022 | 29,358 | 1,305,133 |
| Setareh Seyedkazemi | Chief Development Officer | 2024 | 497,500 | 0 | 25,190 | 199,000 | 9,121 | 1,598,442 |
| Laurent Fischer | Chief Executive Officer, President | 2024 | 691,795 | 0 | 171,363 | 415,080 | 13,800 | 4,131,290 |
| Linda Rubinstein | Chief Financial Officer | 2024 | 499,600 | 0 | 0 | 199,840 | 13,800 | 1,605,925 |
| Kishor Peter Soparkar | Chief Operating Officer | 2024 | 509,300 | 0 | 55,437 | 203,720 | 12,597 | 1,843,178 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 155 |
| 2023 | 121 |
| 2022 | 123 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 1,000,000 | 3,600,000 | 0 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 77,041,000 | 77,676,000 | 99,277,000 |
| General And Administrative Expenses | 63,118,000 | 49,915,000 | 57,858,000 |
| Operating Expenses | 140,159,000 | 127,591,000 | 157,135,000 |
| Operating Income | -139,159,000 | -123,991,000 | -157,135,000 |
| Net Income | -130,927,000 | -117,165,000 | -154,536,000 |
| Earnings Per Share Basic | -6.62 | -1.16 | -1.56 |
| Earnings Per Share Diluted | -6.62 | -1.16 | -1.56 |
| Weighted Average Shares Outstanding Basic | 19,782,000 | 100,824,000 | 99,251,000 |
| Weighted Average Shares Outstanding Diluted | 19,782,000 | 100,824,000 | 99,251,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 60,652,000 | 75,000,000 | 68,431,000 |
| Marketable Securities Current | 65,039,000 | 21,526,000 | 117,158,000 |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 131,300,000 | 102,773,000 | 190,595,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 11,607,000 | 14,764,000 | 34,927,000 |
| Other Assets Non Current | 1,347,000 | 1,231,000 | 1,413,000 |
| Total Assets Non Current | 48,541,000 | 70,237,000 | 117,777,000 |
| Total Assets | 179,841,000 | 173,010,000 | 308,372,000 |
| Accounts Payable | 1,610,000 | 1,921,000 | 2,238,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 22,898,000 | 24,914,000 | 32,246,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 192,000 | 0 | 1,047,000 |
| Total Liabilities Non Current | 86,229,000 | 64,627,000 | 94,608,000 |
| Total Liabilities | 109,127,000 | 89,541,000 | 126,854,000 |
| Common Stock | 2,000 | 10,000 | 10,000 |
| Retained Earnings | -1,066,951,000 | -919,777,000 | -802,612,000 |
| Accumulated Other Comprehensive Income | -407,000 | -473,000 | -1,531,000 |
| Total Shareholders Equity | 70,714,000 | 83,469,000 | 181,518,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 3,653,000 | 5,644,000 | 6,528,000 |
| Share Based Compensation Expense | 14,350,000 | 17,569,000 | 20,079,000 |
| Other Non Cash Income Expense | 39,000 | -1,000 | 1,417,000 |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -262,000 | -369,000 | 845,000 |
| Change In Other Liabilities | 3,021,000 | -5,206,000 | 64,000 |
| Cash From Operating Activities | -92,462,000 | -90,902,000 | -108,091,000 |
| Purchases Of Marketable Securities | 101,901,000 | 36,718,000 | 104,363,000 |
| Sales Of Marketable Securities | 60,400,000 | 134,401,000 | 0 |
| Acquisition Of Property Plant And Equipment | 388,000 | 808,000 | 11,816,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -41,889,000 | 96,875,000 | 141,720,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 120,003,000 | 69,000 | 607,000 |
| Change In Cash | -14,348,000 | 6,042,000 | 34,236,000 |
| Cash At End Of Period | 54,901,000 | 70,972,000 | 56,256,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -6.62 | -1.16 | -1.56 |
| Price To Earnings Ratio | -0.7054 | -6.4897 | -3.7147 |
| Earnings Growth Rate | 470.6897 | -25.641 | 5.4054 |
| Price Earnings To Growth Ratio | -0.0015 | 0.2531 | -0.6872 |
| Book Value Per Share | 3.5747 | 0.8279 | 1.8289 |
| Price To Book Ratio | 1.3064 | 9.0932 | 3.1686 |
| Ebitda | -127,274,000 | -111,521,000 | -148,008,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 496,000 | -14,519,000 | 8,395,000 |
| Free Cash Flow | -92,958,000 | -76,383,000 | -116,486,000 |
| Return On Equity | -1.8515 | -1.4037 | -0.8514 |
| One Year Beta | 1.4271 | 0.3645 | 0.7789 |
| Three Year Beta | 0.8084 | 0.7386 | 1.1896 |
| Five Year Beta | 1.1379 | 1.1452 | 1.1854 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Machado Patrick | Director | 2025-06-17 | 10,450 | A | 10,450 |
| Machado Patrick | Director | 2025-06-17 | 3,140 | A | 3,140 |
| Nicholson, C. David | Director | 2025-06-17 | 10,450 | A | 10,450 |
| Hong Soo | Director | 2025-06-17 | 10,450 | A | 10,450 |
| Lupher, Jr. Mark L. | Director | 2025-06-17 | 10,450 | A | 10,450 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Sound Income Strategies, LLC | 2025-09-30 | 5 | 1 | 5 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 3,631 | 1,689 | 2.1498 |
| Squarepoint Ops LLC | 2025-06-30 | 46,552 | 21,652 | 2.15 |
| MORGAN STANLEY | 2025-06-30 | 113,815 | 52,937 | 2.15 |
| CAPTRUST FINANCIAL ADVISORS | 2025-06-30 | 21,500 | 10,000 | 2.15 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | Avantis U.S. Small Cap Equity ETF | AVSC | 6,843 | 21,076.44 | 0.0011 |
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | Institutional Class | AVSBX | 103 | 317.24 | 0.0003 |
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | G Class | AVSCX | 103 | 317.24 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 23,608 | 72,712.64 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 29,466 | 90,755.28 | 0.0001 |